![Acumen Pharmaceuticals Inc](/common/images/company/N_ABOS.png)
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets... Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Show more
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024Initiation of a Phase 1 study to support a...
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.26 | 9.73782771536 | 2.67 | 3.2 | 2.59 | 600970 | 2.95699397 | CS |
4 | 0.7 | 31.3901345291 | 2.23 | 3.2 | 2.08 | 479312 | 2.54739526 | CS |
12 | -0.26 | -8.15047021944 | 3.19 | 3.92 | 2.08 | 329031 | 2.76440033 | CS |
26 | -0.72 | -19.7260273973 | 3.65 | 5.09 | 2.08 | 336798 | 3.30518692 | CS |
52 | -4.77 | -61.9480519481 | 7.7 | 7.98 | 1.8101 | 449655 | 4.12060369 | CS |
156 | -14.83 | -83.5022522523 | 17.76 | 20.29 | 1.8101 | 415266 | 6.93579661 | CS |
260 | -22.14 | -88.3127243718 | 25.07 | 26.98 | 1.8101 | 413353 | 7.05892508 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.